德国单倍体移植联合移植后环磷酰胺与10/10相合无关供者移植联合抗胸腺细胞球蛋白的结局比较
该注册库回顾性研究比较了2010至2020年德国成人血液系统恶性肿瘤患者中,10/10相合无关供者移植联合抗胸腺细胞球蛋白方案(n=7050)与单倍体移植联合移植后环磷酰胺(n=487)的结局。结果显示10/10相合无关供者组的总生存、无病生存和无移植物抗宿主病无复发生存均更优,且急性及慢性移植物抗宿主病风险更低,但单倍体组复发率更低。
要点
- 10/10相合无关供者联合抗胸腺细胞球蛋白组的总生存、无病生存和无移植物抗宿主病无复发生存均优于单倍体联合移植后环磷酰胺组。
- 单倍体联合移植后环磷酰胺组的2-4级急性移植物抗宿主病、3-4级急性移植物抗宿主病和慢性移植物抗宿主病风险均高于10/10相合无关供者组。
- 单倍体联合移植后环磷酰胺组的复发率低于10/10相合无关供者组。
核心结论
- 在德国,与单倍体移植联合移植后环磷酰胺相比,10/10相合无关供者移植联合抗胸腺细胞球蛋白可降低移植物抗宿主病发生率并提高生存率。
研究设计与样本
- 该研究为注册库回顾性研究,纳入2010至2020年德国成人血液系统恶性肿瘤患者,比较10/10相合无关供者移植联合抗胸腺细胞球蛋白方案(n=7050)与单倍体移植联合移植后环磷酰胺(n=487)的结局。
- 采用Cox比例风险回归和竞争风险回归模型比较结局。
主要发现
- 10/10相合无关供者组的总生存优于单倍体联合移植后环磷酰胺组(HR 1.27,95%CI 1.10-1.47,P=0.001)。
- 10/10相合无关供者组的无病生存优于单倍体联合移植后环磷酰胺组(HR 1.17,95%CI 1.02-1.34,P=0.022)。
- 10/10相合无关供者组的无移植物抗宿主病无复发生存优于单倍体联合移植后环磷酰胺组(HR 1.34,95%CI 1.19-1.50,P<0.001)。
- 单倍体联合移植后环磷酰胺组的2-4级急性移植物抗宿主病风险高于10/10相合无关供者组(HR 1.46,95%CI 1.25-1.71,P<0.001)。
- 单倍体联合移植后环磷酰胺组的3-4级急性移植物抗宿主病风险高于10/10相合无关供者组(HR 1.74,95%CI 1.37-2.20,P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the best curative treatment modality for many malignant hematologic disorders. In the absence of a matched related donor, matched unrelated donors (MUDs) and haploidentical donors are the most important stem cell sources. In this registry-based retrospective study, we compared the outcomes of allo-HSCTs from 10/10 MUDs with antithymocyte globulin (ATG)-based regimens (n = 7050) vs haploidentical transplants (Haplo-Tx) using posttransplant cyclophosphamide (PT-CY Haplo; n = 487) in adult patients with hematologic malignancies between 2010 and 2020. Cox proportional hazard-and competing risks regression models were formed to compare the outcomes. Overall survival (OS), Disease-free survival (DFS), and graft-versus-host disease (GVHD)-free and relapse-free survival (GRFS) were superior for 10/10 MUDs (OS [hazard ratio (HR), 1.27; 95% confidence interval (CI), 1.10-1.47; P = .001]; DFS [HR, 1.17; CI, 1.02-1.34; P = .022]; GRFS [HR, 1.34; CI, 1.19-1.50; P < .001]). The risk of acute GVHD (aGVHD) grade 2 to 4, aGVHD grade 3 to 4, and chronic GVHD (cGVHD) was higher in the PT-CY Haplo group than the 10/10 MUD group (aGVHD grade 2-4 [HR, 1.46; CI, 1.25-1.71; P < .001]; aGVHD grade 3-4 [HR, 1.74; CI, 1.37- 2.20; P < .001]; cGVHD [HR, 1.30; CI, 1.11-1.51; P = .001]). A lower incidence of relapse was observed in the PT-CY Haplo group (relapse: HR, 0.83; CI, 0.69-0.99; P = .038). Unrelated 10/10 matched transplantation with ATG leads to lower GVHD rates and improved survival rates compared with PT-CY Haplo transplantation in Germany.
引用
- Arslan A, Labuhn S, Sala E, et al. Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany. Blood Adv. 2024. PMID: 39368803. doi:10.1182/bloodadvances.2024013719
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。